Company intelligence / Profile preview

Alkapharmics SARL

Switzerland

Ownership: Private
Development stage: Preclinical

Overview

Developing novel allosteric GPCR modulating small molecules that selectively increase production of cyclic adenosine monophosphate (cAMP) in the presence of inflammation, resulting in selective regulation of pro- and anti-inflammatory molecules in innate and adaptive immune cells

Therapeutic areas: Immunology
Modalities: Small molecules (allosteric GPCR modulators)
Industry: Biotech

Beyond the preview

Go deeper on Alkapharmics SARL.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alkapharmics SARL.

Explore the full profile